Koss Olinger Consulting LLC Has $989,000 Stock Holdings in Royalty Pharma PLC (NASDAQ:RPRX)

Key Points

• Koss Olinger Consulting LLC increased its stake in Royalty Pharma PLC by 201.5%, holding 31,756 shares valued at approximately $989,000 at the end of the first quarter.
• Wall Street analysts have recently upgraded Royalty Pharma, with Citigroup raising their price target from $40 to $42 and Morgan Stanley from $51 to $54, indicating a generally positive outlook for the stock.
• Royalty Pharma announced a quarterly dividend of $0.22 per share, representing an annualized yield of 2.3%, which will be paid to investors on September 10th.

Koss Olinger Consulting LLC raised its stake in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 201.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 31,756 shares of the biopharmaceutical company's stock after purchasing an additional 21,225 shares during the period. Koss Olinger Consulting LLC's holdings in Royalty Pharma were worth $989,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in RPRX. Louisbourg Investments Inc. acquired a new stake in shares of Royalty Pharma in the first quarter worth $28,000. MassMutual Private Wealth & Trust FSB lifted its position in Royalty Pharma by 76.4% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 956 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 414 shares during the period. Allworth Financial LP lifted its position in Royalty Pharma by 41.6% in the first quarter. Allworth Financial LP now owns 1,539 shares of the biopharmaceutical company's stock worth $49,000 after purchasing an additional 452 shares during the period. National Bank of Canada FI lifted its position in Royalty Pharma by 21.8% in the fourth quarter. National Bank of Canada FI now owns 2,074 shares of the biopharmaceutical company's stock worth $53,000 after purchasing an additional 371 shares during the period. Finally, Transce3nd LLC bought a new position in Royalty Pharma in the fourth quarter worth $61,000. Institutional investors and hedge funds own 54.35% of the company's stock.

Royalty Pharma Trading Up 0.7%

NASDAQ:RPRX traded up $0.24 on Wednesday, hitting $36.10. 2,544,683 shares of the stock were exchanged, compared to its average volume of 4,383,322. The stock has a market capitalization of $20.30 billion, a price-to-earnings ratio of 20.86, a P/E/G ratio of 2.36 and a beta of 0.55. Royalty Pharma PLC has a 52 week low of $24.05 and a 52 week high of $38.00. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.26 and a current ratio of 1.26. The company's 50-day moving average price is $35.80 and its 200 day moving average price is $33.66.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its earnings results on Wednesday, August 6th. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.04. The company had revenue of $578.67 million during the quarter, compared to analyst estimates of $750.06 million. Royalty Pharma had a return on equity of 25.54% and a net margin of 44.23%. On average, equities research analysts forecast that Royalty Pharma PLC will post 4.49 earnings per share for the current year.

Royalty Pharma Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be given a $0.22 dividend. The ex-dividend date is Friday, August 15th. This represents a $0.88 annualized dividend and a dividend yield of 2.4%. Royalty Pharma's payout ratio is currently 50.87%.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. Wall Street Zen raised Royalty Pharma from a "hold" rating to a "buy" rating in a research report on Saturday. Citigroup boosted their price target on shares of Royalty Pharma from $40.00 to $42.00 and gave the company a "buy" rating in a research report on Tuesday, July 22nd. Finally, Morgan Stanley lifted their price target on Royalty Pharma from $51.00 to $54.00 and gave the company an "overweight" rating in a report on Thursday, July 10th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $49.00.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.